Expression of the KAI1 Protein in Benign Prostatic Hyperplasia and Prostate Cancer

Overview

Journal Am J Pathol

Publisher Elsevier

Specialty Pathology

Date 1996 Nov 1

PMID 8909232

Citations 18

Authors

T Ueda

T Ichikawa

J Tamaru

A Mikata

K Akakura

S Akimoto

T Imai

O Yoshie

T Shiraishi

R Yatani

H Ito

J Shimazaki

Affiliations

Soon will be listed here.

Abstract

The KAI1 gene, recently identified as a metastatic suppressor gene for prostate cancer, was cloned and was revealed to be identical to the C33/IA4/ R2/4R9 gene. The expression of KAI1 protein was examined immunohistochemically in the tissues from 14 cases of benign prostatic hyperplasia and 46 cases of prostate cancer using mouse monoclonal anti-human C33 antibody. In benign prostatic hyperplasia tissues, KAI1 protein was uniformly expressed in the glandular cell membrane at cell-to-cell borders. The KAI1 protein in the tissues of untreated prostate cancer was also located at similar sites to those of benign prostatic hyperplasia, but the percentage of strongly positive cancer cells was correlated inversely to the Gleason pattern (P < 0.0001, one-way analysis of variance). There was also a statistically inverse correlation between the percentage of KAI1-positive cancer cells and the clinical stage (chi 2 = 9.6; P = 0.0081). In 4 cancer death cases relapsed from endocrine therapy, KAI1 protein was not stained in either primary or metastatic foci. These results indicate that the expression of KAI1 protein correlates to tumor characteristics in prostate cancer.

Citing Articles

Role of a metastatic suppressor gene KAI1/CD82 in the diagnosis and prognosis of breast cancer.

Al-Khater K, Almofty S, Ravinayagam V, Alrushaid N, Rehman S Saudi J Biol Sci. 2021; 28(6):3391-3398.

PMID: 34121877 PMC: 8176039. DOI: 10.1016/j.sjbs.2021.03.001.

Gene expression analysis of human prostate cell lines with and without tumor metastasis suppressor CD82.

Dodla P, Bhoopalan V, Khoo S, Miranti C, Sridhar S BMC Cancer. 2020; 20(1):1211.

PMID: 33298014 PMC: 7724878. DOI: 10.1186/s12885-020-07675-7.

10 Year Biochemical Failure Free Survival of Men with CD82 Positive Primary Circulating Prostate Cells Treated by Radical Prostatectomy.

Murray N, Aedo S, Fuentealba C, Reyes E Asian Pac J Cancer Prev. 2018; 19(6):1577-1583.

PMID: 29936782 PMC: 6103576. DOI: 10.22034/APJCP.2018.19.6.1577.

The lichen secondary metabolite atranorin suppresses lung cancer cell motility and tumorigenesis.

Zhou R, Yang Y, Park S, Nguyen T, Seo Y, Lee K Sci Rep. 2017; 7(1):8136.

PMID: 28811522 PMC: 5557893. DOI: 10.1038/s41598-017-08225-1.

Lichen Secondary Metabolite, Physciosporin, Inhibits Lung Cancer Cell Motility.

Yang Y, Park S, Nguyen T, Yu Y, Nguyen T, Sun E PLoS One. 2015; 10(9):e0137889.

PMID: 26371759 PMC: 4570789. DOI: 10.1371/journal.pone.0137889.

References

Imai T, Fukudome K, Takagi S, Nagira M, Furuse M, Fukuhara N . C33 antigen recognized by monoclonal antibodies inhibitory to human T cell leukemia virus type 1-induced syncytium formation is a member of a new family of transmembrane proteins including CD9, CD37, CD53, and CD63. J Immunol. 1992; 149(9):2879-86. View

Adachi M, Taki T, Ieki Y, Huang C, Higashiyama M, Miyake M . Correlation of KAI1/CD82 gene expression with good prognosis in patients with non-small cell lung cancer. Cancer Res. 1996; 56(8):1751-5. View

Prout Jr G . Proceedings: Diagnosis and staging of prostatic carcinoma. Cancer. 1973; 32(5):1096-103. DOI: 10.1002/1097-0142(197311)32:5<1096::aid-cncr2820320514>3.0.co;2-k. View

Emrich L, Priore R, Murphy G, Brady M . Prognostic factors in patients with advanced stage prostate cancer. Cancer Res. 1985; 45(10):5173-9. View

Soloway M, Hardeman S, Hickey D, Raymond J, Todd B, Soloway S . Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer. 1988; 61(1):195-202. DOI: 10.1002/1097-0142(19880101)61:1<195::aid-cncr2820610133>3.0.co;2-y. View

Hotta H, Ross A, Huebner K, Isobe M, Wendeborn S, Chao M . Molecular cloning and characterization of an antigen associated with early stages of melanoma tumor progression. Cancer Res. 1988; 48(11):2955-62. View

Fearon E, Vogelstein B . A genetic model for colorectal tumorigenesis. Cell. 1990; 61(5):759-67. DOI: 10.1016/0092-8674(90)90186-i. View

Oren R, Takahashi S, Doss C, Levy R, Levy S . TAPA-1, the target of an antiproliferative antibody, defines a new family of transmembrane proteins. Mol Cell Biol. 1990; 10(8):4007-15. PMC: 360911. DOI: 10.1128/mcb.10.8.4007-4015.1990. View

Boucheix C, Benoit P, Frachet P, Billard M, Worthington R, Gagnon J . Molecular cloning of the CD9 antigen. A new family of cell surface proteins. J Biol Chem. 1991; 266(1):117-22. View

10.

Gaugitsch H, Hofer E, Huber N, Schnabl E, Baumruker T . A new superfamily of lymphoid and melanoma cell proteins with extensive homology to Schistosoma mansoni antigen Sm23. Eur J Immunol. 1991; 21(2):377-83. DOI: 10.1002/eji.1830210219. View

11.

Bergerheim U, Kunimi K, Collins V, Ekman P . Deletion mapping of chromosomes 8, 10, and 16 in human prostatic carcinoma. Genes Chromosomes Cancer. 1991; 3(3):215-20. DOI: 10.1002/gcc.2870030308. View

12.

Horejsi V, Vlcek C . Novel structurally distinct family of leucocyte surface glycoproteins including CD9, CD37, CD53 and CD63. FEBS Lett. 1991; 288(1-2):1-4. DOI: 10.1016/0014-5793(91)80988-f. View

13.

Kunimi K, Bergerheim U, Larsson I, Ekman P, Collins V . Allelotyping of human prostatic adenocarcinoma. Genomics. 1991; 11(3):530-6. DOI: 10.1016/0888-7543(91)90059-n. View

14.

Fukudome K, Furuse M, Imai T, Nishimura M, Takagi S, Hinuma Y . Identification of membrane antigen C33 recognized by monoclonal antibodies inhibitory to human T-cell leukemia virus type 1 (HTLV-1)-induced syncytium formation: altered glycosylation of C33 antigen in HTLV-1-positive T cells. J Virol. 1992; 66(3):1394-401. PMC: 240862. DOI: 10.1128/JVI.66.3.1394-1401.1992. View

15.

Gil M, Vita N, Miloux B, Chalon P, Kaghad M, Marchiol-Fournigault C . A member of the tetra spans transmembrane protein superfamily is recognized by a monoclonal antibody raised against an HLA class I-deficient, lymphokine-activated killer-susceptible, B lymphocyte line. Cloning and preliminary functional studies. J Immunol. 1992; 148(9):2826-33. View

16.

Schroder F, Hermanek P, Denis L, Fair W, Gospodarowicz M, Pavone-Macaluso M . The TNM classification of prostate cancer. Prostate Suppl. 1992; 4:129-38. DOI: 10.1002/pros.2990210521. View

17.

Umbas R, Schalken J, Aalders T, Carter B, Karthaus H, Schaafsma H . Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res. 1992; 52(18):5104-9. View

18.

Lesley J, HYMAN R, Kincade P . CD44 and its interaction with extracellular matrix. Adv Immunol. 1993; 54:271-335. DOI: 10.1016/s0065-2776(08)60537-4. View

19.

Kondoh M, Ueda M, Ichihashi M, Mishima Y . Decreased expression of human melanoma-associated antigen ME491 along the progression of melanoma pre-canceroses to invasive and metastatic melanomas. Melanoma Res. 1993; 3(4):241-5. View

20.

Konishi N, Nakaoka S, Tsuzuki T, Matsumoto K, Kitahori Y, Hiasa Y . Expression of nm23-H1 and nm23-H2 proteins in prostate carcinoma. Jpn J Cancer Res. 1993; 84(10):1050-4. PMC: 5919063. DOI: 10.1111/j.1349-7006.1993.tb02800.x. View